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Introduction
Gadolinium-based contrast agents (GBCAs) are 
widely used to improve diagnostic accuracy of mag-
netic resonance imaging (MRI) in a broad spectrum 
of diseases. Especially for patients with multiple 
sclerosis (MS), MRI forms a cornerstone in diagno-
sis and contributes significantly to treatment deci-
sions.1 GBCAs have been used in clinical practice 
for more than 25 years, and no detrimental long-term 
effects have been described.2 However, a growing 
body of evidence3–15 gives rise to the concern that 
gadolinium (Gd) is deposited in deep grey matter of 
the brain, especially in the dentate nucleus (DN) 
and, to a much lesser degree, the basal ganglia. The 
apprehension arose initially from observational 
studies performed in adults,3–10 further supported by 
data in paediatric cohorts11,12 and animal experi-
ments.13–15 Here, it is assumed that different types of 
GBCAs confer different risks with linear contrast 
agents (e.g. gadopentetate dimeglumine (Gd-DTPA, 
Magnevist®)) being more likely to accumulate than 
macrocyclic agents (e.g. gadobutrol (Gd-BT-DO3A, 
Gadovist®)).
The clinical implications of Gd deposition in the brain 
are uncertain. However, similar to the situation when 
nephrogenic systemic fibrosis was first described, 
there is growing concern about the long-term safety 
of GBCAs.16–18
In all except two of the original studies on cerebral Gd 
deposition,9,10 patients with MS were excluded. This 
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Abstract
Background: Previous studies have postulated an association between dentate nucleus T1 hyperintensity 
and multiple sclerosis (MS)-related progressive neurodegeneration. Therefore, MS patients have been 
excluded from most studies investigating brain deposition of gadolinium-based contrast agents (GBCAs).
Objective: To study the hypothesis that dentate nucleus T1 hyperintensity in MS patients is associated 
with GBCA administration.
Methods: In a cohort of 97 MS patients, the dentate-to-pons signal intensity ratio (DPSIR) was calcu-
lated for 265 consecutive T1-weighted magnetic resonance (MR) scans (including sessions with and 
without the administration of GBCA). Patients exclusively received either gadopentetate dimeglumine 
(Gd-DTPA, linear) or gadobutrol (Gd-BT-DO3A, macrocyclic).
Results: In patients receiving Gd-DTPA, DPSIR increased significantly between the first and the last scan 
(+0.009, p < 0.001), and following magnetic resonance imaging (MRI) with Gd-DTPA administration as 
compared to following an MRI without Gd-DTPA administration (+0.005 vs −0.001; p = 0.022). Addition-
ally, there was a positive linear relationship between the number of Gd-DTPA administrations and the 
increase in DPSIR (p = 0.017). No DPSIR increase was observed after Gd-BT-DO3A administration.
Conclusion: Dentate nucleus T1 hyperintensity in MS patients is associated with Gd-DTPA (but not Gd-
BT-DO3A) administration, suggesting an alternative explanation for the association of T1 hyperintensity 
with disease duration and severity.
Keywords: Multiple sclerosis, magnetic resonance imaging, gadolinium
Date received: 10 July 2016; revised: 15 August 2016; accepted: 29 August 2016
Correspondence to:  
F Paul  
NeuroCure Clinical Research 
Center, NeuroCure Cluster 
of Excellence, Charité – 
Universitätsmedizin Berlin, 
Charitéplatz 1, Berlin 10117, 
Germany. 
friedemann.paul@charite.
de
Ludwig Schlemm 
Department of Neurology, 
Charité – Universitätsmedizin 
Berlin, Berlin, Germany
Claudia Chien  
Jan Dörr  
Alexander U Brandt 
Michael Scheel  
NeuroCure Clinical Research 
Center, NeuroCure Cluster 
of Excellence, Charité – 
Universitätsmedizin Berlin, 
Berlin, Germany
Judith Bellmann-Strobl 
NeuroCure Clinical Research 
Center, NeuroCure Cluster 
of Excellence, Charité 
– Universitätsmedizin 
Berlin, Berlin, Germany/
Experimental and Clinical 
Research Center, Max 
Delbrueck Center for 
Molecular Medicine and 
Charité – Universitätsmedizin 
Berlin, Berlin, Germany
Jens Wuerfel  
NeuroCure Clinical Research 
Center, NeuroCure Cluster 
of Excellence, Charité 
– Universitätsmedizin 
Berlin, Berlin, Germany/
Medical Image Analysis 
Center (MIAC AG), Basel, 
Switzerland
Friedemann Paul 
Department of Neurology, 
Charité – Universitätsmedizin 
Berlin, Berlin, Germany/
NeuroCure Clinical Research 
Center, NeuroCure Cluster 
of Excellence, Charité 
– Universitätsmedizin 
Berlin, Berlin, Germany/
Experimental and Clinical 
Research Center, Max 
Delbrueck Center for 
Molecular Medicine and 
Charité – Universitätsmedizin 
Berlin, Berlin, Germany
670738MSJ0010.1177/1352458516670738Multiple Sclerosis JournalL Schlemm, C Chien
research-article2016
Original Research Paper
Multiple Sclerosis Journal 23(7)
964 journals.sagepub.com/home/msj
was likely due to previous studies reporting DN 
hyperintensity on T1-weighted (T1w) MRI in MS 
patients and postulating a correlation with disease 
severity and duration.19–21 Yet, the concern about Gd 
deposition is of particularly high relevance to MS 
patients: they are mostly young at the age of diagnosis 
with a long life expectancy22 and usually receive a 
high number of contrast-enhanced scans over the 
years. Furthermore, MS patients are potentially more 
prone to accumulate Gd in their brains because the 
blood–brain barrier may be temporarily compromised 
at the time when magnetic resonance (MR) scans are 
performed. The current discussions about the long-
term safety of GBCAs have already led to anxiety and 
concerns in MS patients. Print and online media are 
frequently reporting on the perceived lack of GBCA 
safety,23 further nourishing feelings of uncertainty 
among patients.
Against this background, we studied in an MS cohort 
the signal intensity increase in the DN on unenhanced 
T1w MRI as a surrogate marker of Gd deposition 
after GBCA administration. We investigated two dif-
ferent types of GBCAs: the linear Gd-DTPA (gado-
pentetate dimeglumine) and the macrocyclic 
Gd-BT-DO3A (gadobutrol). More precisely, we tested 
three hypotheses: (1) there is an increase in the den-
tate-to-pons signal intensity ratio (DPSIR) after mul-
tiple GBCA administrations, (2) DPSIR increases 
more when GBCA was administered during the pre-
ceding MR session as compared to when GBCA was 
not administered and (3) there is an association 
between the change of DPSIR and the number of 
GBCA dosages administered.
Patients and methods
Study design
From our research database, we retrospectively iden-
tified MS patients who participated in long-term 
longitudinal studies and had exclusively received 
either the linear Gd-DTPA at a fixed dosage of 20 mL 
with a concentration of 0.5 mmol/mL (10 mmol per 
dosage) or the macrocyclic Gd-BT-DO3A at a dosage 
of 0.1 mL/kg body weight with a concentration of 
1.0 mmol/mL (mean 7.54 ± 1.46 mmol per dosage) 
according to the manufacturers’ instructions. The 
change of DPSIR on unenhanced magnetization- 
prepared rapid gradient-echo (MPRAGE) sequences 
between the first and the last scan and between two 
subsequent scans were the primary outcomes. The 
exposures were the total number of GBCA adminis-
trations and the type of GBCA that was administered. 
MS subtype, disease severity measured by the 
Extended Disability Status Scale (EDSS), time since 
diagnosis and the time between scans were consid-
ered as potential variables of relevance.
Participants
A total of 50 patients in each GBCA group who had 
received between two and five consecutive MR 
examinations were included in our study. In at least 
one of the examinations (other than the last) GBCA 
was administered. All scans were performed on 1.5 T 
(Siemens Sonata) or 3 T scanners (Siemens TimTrio) 
according to standardized protocols as part of 
clinical studies performed by the NeuroCure 
Clinical Research Center (NCRC) at Charité – 
Universitätsmedizin Berlin, Germany, without change 
of field strength during follow-up. Patients with high 
infratentorial lesion load affecting the DN were 
excluded from further analysis (three participants). 
Patients received MRI at pre-defined intervals with 
administration of GBCA independent of disease 
activity. All patients had a definite diagnosis of MS 
according to previous or current panel criteria.24–26 
None of the included participants had known renal 
impairment. Clinical and demographic data, total 
number and timing of scans with and without admin-
istration of GBCA and the type of GBCA adminis-
tered were retrieved from the research database.
Standard protocol approvals, registrations and 
patient consents
All patients provided written informed consent for 
participation in clinical research at NCRC including 
the acquisition and analysis of clinical and MRI data. 
The local ethics committee approved the study.
Image acquisition and processing
From our local research database native three-
dimensional (3D) T1w images (MPRAGE) 
were downloaded for further analysis (resolution 
1 × 1 × 1 mm3; TR = 2110 ms, TE = 4.38 ms, 
TI = 1100 ms, flip angle 15° for 1.5 T; TR = 1900 ms, 
TE = 3.03 ms, TI = 900 ms, flip angle 9° for 3 T; see 
Appendix for MRI methodology in the Supplementary 
Material for details). Since the DN is usually not 
clearly discernible on T1w and T2-weighted (T2w) 
images, studies in the past predominantly used a 
manual anatomy-based approach to extract signal 
intensities in the DN and pons. For a more objective 
and reproducible assessment, we used an established 
semiautomatic method for the evaluation of the deep 
cerebellar nuclei, that is, the SUIT tool box27–29 
within SPM8 (The FIL Methods Group, Wellcome 
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Trust Centre for Neuroimaging, London) under 
MATLAB (Mathworks, Inc). In this method, the cer-
ebellum and the brainstem are automatically isolated 
by segmentation and cropping. The resulting images 
are registered to a common stereotactic space by 
nonlinear deformation. A DN mask was created from 
Diedrichsen et al.’s29 probabilistic atlas of the deep 
cerebellar nuclei through binarization at a threshold 
of 0.75. An additional pons mask was created manu-
ally (see Figure 1 for an example of mask place-
ment). Mean signal intensities within each mask and 
the DPSIR were calculated for each scan.
The absolute difference of DPSIR between two scans 
was denoted by Δ[DPSIR]. The absolute difference of 
DPSIR between the first and last scan was denoted by 
Δ[DPSIR]total. We also calculated the DPSIR differ-
ence between subsequent scans. If the analysed visit 
followed a visit where GBCA was administered, 
the difference was denoted by Δ[DPSIR]Gd+, other-
wise Δ[DPSIR]Gd− (see Figure 2 for an exemplary 
calculation). Subsequently, we compared subject 
specific means of Δ[DPSIR]Gd+ and Δ[DPSIR]Gd−. 
Additionally, we tested if there was a linear relation-
ship between Δ[DPSIR]total and the number of GBCA 
administrations.
Statistical analysis
Data were analysed using IBM SPSS Statistics ver-
sion 21 (IBM Corp.; Armonk, NY, USA) and 
GraphPad Prism version 6.01 for Windows (GraphPad 
Software, La Jolla, CA, USA). For continuous varia-
bles, normal distribution was confirmed using the 
Shapiro–Wilk test. Normally distributed data are pre-
sented as mean ± standard deviation (SD); non- 
normally distributed continuous variables are pre-
sented as median and range. Proportions between two 
groups were compared using the asymptotic Pearson’s 
chi-square test. Student’s t-test was used to compare 
the means of normally distributed variables. To exam-
ine the relationship between the number of GBCA 
administrations and DPSIR change, a univariate gen-
eral linear model with a linear contrast was employed. 
Consistency between the manual and the automatic 
methodology was estimated using the intra-class cor-
relation coefficient and Passing–Bablok regression.30 
When the absolute effect of GBCA administration on 
DN T1 signal intensity was tested, a one-tail p value 
was used assuming a positive association between 
GBCA administration and DN T1 signal intensity 
increase. In all other cases, a two-tail p value was 
used. A p value <0.025 was considered statistically 
significant to account for the simultaneous examina-
tion of two different agents.
Results
Patient characteristics of the study population and 
radiological data according to type of GBCA 
Figure 1. Placement of masks for the dentate nuclei and 
the pons. After registration to a standard space, the ratio 
between the signal intensity within the dentate nucleus 
mask and the pons mask was calculated. Dentate nuclei 
masks were derived from a probabilistic atlas of deep 
cerebellar nuclei. The pons mask was created manually. 
(a) The placement of the two masks in standard space. (b) 
Axial unenhanced MPRAGE images of an example patient 
on MRI visit 1 (baseline visit, upper panel) and MRI visit 
5 after four administrations of Gd-DTPA (lower panel). 
Dentate-to-pons signal intensity ratio is higher on visit 5 
than on visit 1.
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are displayed in Table 1. Both GBCA groups were 
comparable regarding age and sex. MS subtype and 
EDSS score differed significantly between the two 
GBCA groups. Time between scans was approxi-
mately 1 month longer in the Gd-DTPA group as com-
pared to the Gd-BT-DO3A group. The table also 
contains the number of patients in each group for 
which we could calculate the change of DPSIR after 
MR sessions with and without GBCA administration. 
The distribution of the total amount of GBCA admin-
istrations was not significantly different between the 
Gd-DTPA and the Gd-BT-DO3A group (mean, 2.08 
vs 2.02; median, 2.00 in both groups; range, 1–3 in 
both groups; chi-square = 0.380; df = 2; p = 0.827). 
DPSIR at baseline was significantly higher in the 
Gd-DTPA group, possibly reflecting a higher number 
of contrast-enhanced MRI examinations before enter-
ing the study (p < 0.05 for bivariate correlation).
To evaluate the validity of the semi-automated 
approach, we compared the values of the averaged 
mean signal intensities of the DNs with those derived 
from manually created masks for 44 scans (17% of 
the total number of scans). Passing–Bablok regres-
sion confirmed the comparability of the two methods 
with the confidence intervals of the slope and the 
intercept encompassing one and zero, respectively 
(slope: 0.96 (0.79–1.14), intercept: 23.49 (−50.43 to 
101.64)). The intra-class correlation coefficient for 
single measures in an absolute agreement two-way 
mixed model was 0.79, indicating good agreement.
We tested the hypothesis that DPSIR increases after 
multiple GBCA administrations. First, we evaluated 
the absolute change of DPSIR between the first and 
the last scan for all patients irrespective of the number 
of GBCA administrations they had received. Here, 
DPSIR increased significantly between the first 
and the last scan in the Gd-DTPA group 
(Δ[DPSIR]total = 0.009 ± 0.017; p < 0.001) but not in the 
Gd-BT-DO3A group (Δ[DPSIR]total = −0.002 ± 0.015; 
p = 0.847; Figure 3). Second, we separately studied 
those 31 participants that had received three dosages 
of GBCA. Also in these patients, DPSIR increased 
Figure 2. Exemplary study protocol for a representative patient with five consecutive MR scans.
This exemplary patient received five MR scans per protocol: four with GBCA administrations (visit 1, 2, 4 and 5) and one without 
(visit 3). Note that the GBCA administration at visit 5 will not have any effect on the analysis as we analysed at each visit the 
MPRAGE sequence prior to the injection of contrast. In this patient, the absolute difference of the dentate-to-pons signal intensity 
ratio (DPSIR) between the first and the last scan (Δ[DPSIR]total) would be calculated as ∆[ ]DPSIR DPSIR DPSIRtotal visit 5 visit= − 1 . 
The mean DPSIR change following MRI visits with GBCA administration (Δ[DPSIR]Gd+) – in this example visits 2, 3 and 5 – would 
be calculated as ∆[ ] [( ) (DPSIR DPSIR DPSIR DPSIR DPSIRGd+ visit visit visit v= − + −2 1 3 isit visit 5 visitDPSIR DPSIR2 4 3) ( )] /+ − . The mean 
DPSIR change following MRI visits without GBCA administration (Δ[DPSIR]Gd−) – in this example visit 4 – would be calculated as 
∆[ ] ( )DPSIR DPSIR DPSIRGd visit visit− = −4 3 . Also shown is our signal increase hypothesis with an increase in DPSIR after MR sessions 
with GBCA administration and no change of DPSIR after MR sessions without GBCA administration.
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Table 1. Patient characteristics and radiological data according to type of GBCA.
Variable Gd-DTPA group Gd-BT-DO3A group p valuea
Demographic data
 Total number of participantsb 49 48 –
 Age (years), mean ± SD 45.4 ± 11.5 44.7 ± 9.9 0.762
 Female sex (%) 56 56 0.522
Clinical data
 MS subtype
  RRMS (%), proportion 40 81 <0.05
  PPMS (%), proportion 21 11  
  SPMS (%), proportion 39 8  
 EDSS score, median (range) 4.5 (0.0–8.0) 2.5 (0.0–6.5) <0.05c
 Disease duration (years), median (range) 10 (0–37) 8 (1–26) 0.572
Radiological data
 Total number of MR scans 149 116 –
 Total number of GBCA administrationsd 79 93 –
 Number of MR scans per patient, median (range) 4 (2–5) 3 (2–5) –
  Number of GBCA administrations per patient available for 
subsequent evaluation,d median (range)
2 (1–3) 2 (1–3) –
 Amount of GBCA administered during enhanced scans (mL) 20 (fixed dose) 0.1 per kg body weight –
 DPSIR at baseline 1.09 ± 0.33 1.00 ± 0.06 <0.05
 Time between first and last scan (years), mean ± SD 2.49 ± 1.40 1.88 ± 0.86 <0.05
 Time between subsequent MR scans (years), mean ± SD 0.88 ± 0.25 0.80 ± 0.24 <0.05
 Time after enhanced scan (years), mean ± SD 0.81 ± 0.28 (n = 49) 0.82 ± 0.16 (n = 48) 0.883
 Time after unenhanced scan (years), mean ± SD 0.96 ± 0.08 (n = 28) 0.92 ± 0.134 (n = 11) 0.466
 Field strength
  1.5 T (%), proportion of scans 100 71 <0.05
  3 T (%), proportion of scans 0 29  
GBCA: gadolinium-based contrast agent; Gd-DTPA: gadopentetate dimeglumine; Gd-BT-DO3A: gadobutrol; SD: standard deviation; MS: multiple sclerosis; 
RRMS: relapsing-remitting multiple sclerosis; PPMS: primary-progressive multiple sclerosis; SPMS: secondary-progressive multiple sclerosis; EDSS: Extended 
Disability Status Scale; MR: magnetic resonance; DPSIR: dentate-to-pons signal intensity ratio.
ap value for comparison between the two groups.
bThree participants were excluded because of high infratentorial lesion load.
cMann–Whitney U test.
dNumber of GBCA administrations available for subsequent evaluation, that is, not including the last MR scan a patient received.
significantly between the first and the last scan in the 
Gd-DTPA group (Δ[DPSIR]total = 0.015 ± 0.011, n = 17; 
p < 0.001), but not in the Gd-BT-DO3A group (Δ 
[DPSIR]total = −0.006 ± 0.015, n = 14; p = 0.935).
To investigate the effect of a single GBCA adminis-
tration on DN T1 signal intensity, patient-specific 
means of the change of the DN T1 signal intensity 
ratio following an MR session with GBCA adminis-
tration (Δ[DPSIR]Gd+) and without GBCA administra-
tion (Δ[DPSIR]Gd−) were calculated. In both GBCA 
groups, the change of DPSIR after an MR session 
without GBCA administration was not significantly 
different from zero (Gd-DTPA: −0.001 ± 0.009, 
p = 0.679; Gd-BT-DO3A: 0.002 ± 0.008, p = 0.856). 
On the other hand, the change of DPSIR after an MR 
session with GBCA administration was significantly 
higher than zero in the Gd-DTPA group, but not in the 
Gd-BT-DO3A group (Gd-DTPA: 0.005 ± 0.015, 
p = 0.018; Gd-BT-DO3A: −0.001 ± 0.009, p = 0.876). 
Using data from patients for which both Δ[DPSIR]Gd+ 
and Δ[DPSIR]Gd− were estimable, analysis by a paired 
t-test demonstrated that in the Gd-DTPA group, but 
not in the Gd-BT-DO3A group, Δ[DPSIR]Gd+ was sig-
nificantly higher than Δ[DPSIR]Gd− (0.005 ± 0.015 vs 
−0.001 ± 0.009, n = 28; p = 0.022; Figure 4). The iso-
lated effect of a single administration of Gd-DTPA on 
DPSIR was therefore estimated to be +0.005.
Our third hypothesis was that patients who received a 
higher number of GBCA administrations would show 
a larger increase in DPSIR between the first and the 
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last scan. In the Gd-DTPA group, analysis of variance 
with linear contrast demonstrated a significant posi-
tive association between the number of GBCA admin-
istrations and the change of DPSIR between the first 
and the last scan (p = 0.017) with a contrast estimate 
of 0.009 (confidence interval (CI), 0.001–0.018). No 
significant association was seen in the Gd-BT-DO3A 
group (p = 0.992, Figure 5).
Discussion
In the context of Gd accumulation in brain tissue, MS 
patients have been excluded from almost all previous 
studies due to the hypothesis that DN T1 hyperinten-
sity and MS disease severity and duration are 
positively correlated.19–21 We therefore evaluated 
if repeated administrations of the linear GBCA 
Gd-DTPA (gadopentetate dimeglumine, Magnevist®) 
and the macrocyclic GBCA Gd-BT-DO3A 
(gadobutrol, Gadovist®) are associated with increased 
signal intensity in the DN of MS patients on unen-
hanced T1w MRI. Our data show that the administra-
tion of Gd-DTPA is associated with a significant 
signal increase in a linear fashion. This effect can 
already be observed after a single administration. 
The effect size for the change of DPSIR was +0.005 
per Gd-DTPA administration. This is in agreement 
with data from a study cohort of non-MS patients 
published by Radbruch et al.,6 who reported a DPSIR 
difference of +0.04 after 7.32 contrast-enhanced MRI 
examinations, corresponding to a DPSIR difference 
of +0.005 per Gd-DTPA-administration.
Figure 3. Change of the dentate-to-pons signal intensity 
ratio between the first and the last scan.
Change of the dentate-to-pons signal intensity ratio (DPSIR) 
between the first and the last scan (Δ[DPSIR]total) in all patients 
according to GBCA group. In the Gd-DTPA group, but not in 
the Gd-BT-DO3A group, the absolute change of DPSIR between 
the first and the last scan was significantly higher than zero. 
Displayed are means, error bars represent standard error of the 
mean. ****p < 0.001; ns, not statistically significant. For details 
and statistical tests, see text.
Figure 4. Change of the dentate-to-pons signal intensity 
ratio between two subsequent scans.
Change of the dentate-to-pons signal intensity ratio (DPSIR) 
between two subsequent scans after MR sessions with and without 
GBCA administration (Δ[DPSIR]Gd+/−) according to GBCA group. 
In the Gd-DTPA group, the increase in DPSIR after an MR session 
with GBCA administration was significantly higher than zero and 
also significantly larger than the increase in DPSIR after an MR 
session without GBCA administration. No statistical difference 
was seen in the Gd-BT-DO3A group. Displayed are means, 
error bars represent standard error of the mean. *p < 0.05; ns, not 
statistically significant. For details and statistical tests, see text.
Figure 5. Association between the number of GBCA 
administrations and the change of the dentate-to-pons 
signal intensity ratio.
Association between the total number of GBCA administrations 
and the change of the dentate-to-pons signal intensity ratio 
(DPSIR) between the first and the last scan (Δ[DPSIR]total) 
according to GBCA group. In the Gd-DTPA group, there was a 
significant positive linear relationship between the total number of 
GBCA administrations and the change of DPSIR between the first 
and the last scan; a higher number of GBCA administrations was 
associated with a significantly larger increase in DPSIR. No such 
relationship was found in the BT-DO3A group. *p < 0.05 for linear 
increase; ns, not statistically significant. For details and statistical 
tests, see text.
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In contrast, the administration of Gd-BT-DO3A was 
not associated with an increase in DPSIR in our study. 
Our study hence confirms that Gd from macrocyclic 
GBCAs is less likely to accumulate in deep cerebral 
grey matter compared to that of the thermodynami-
cally less stable linear GBCAs.5–7,17,31
Two studies have examined the effect of serial admin-
istrations of GBCAs on DN T1 hyperintensity in MS 
patients. Both studies were limited by a small sample 
size and lack of control for the natural course of the 
disease, which was postulated to influence the devel-
opment of T1 hyperintense dentate nuclei (see discus-
sion below).19,21 In one of these studies, Errante 
et al.9 reported an association between a progressive 
increase in T1 signal intensity of the DN in unen-
hanced MR images with cumulative doses of intrave-
nously administered gadodiamide (a linear GBCA) in 
38 patients with relapsing-remitting multiple sclerosis 
(RRMS), which is similar to our findings. In the sec-
ond study and contrary to our results, Stojanov et al.10 
reported a correlation between the cumulative dose of 
the macrocyclic Gd-BT-DO3A (mean number of 
GBCA administrations: 4.74) and signal intensity 
within the DN and globus pallidus on unenhanced 
T1w MRI in 58 patients with RRMS. The latter of the 
two studies was criticized for poor methodology such 
as different intervals of contrast administration and 
the determination of regions of interest solely based 
on anatomically consensus.32,33 Results regarding 
Gd-BT-DO3A could not be replicated in our study 
with a lower mean number of GBCA administrations 
of 2.02 and also not in the non-MS cohort of Radbruch 
et al.7
As per protocol, in our study, GBCA was not admin-
istered during each MR session, which allowed for 
the first time to investigate the effect of a single 
GBCA administration on the change of DPSIR and to 
account for the confounding factor ‘progressive neu-
rodegeneration’: disease progression could explain a 
DPSIR increase between the first and the last scan, 
but not a DPSIR increase following an MRI with 
GBCA administration as compared to following an 
MRI without GBCA administration. Additionally, in 
contrast to previous studies, we implemented a semi-
automated image pre-processing method using an 
established probabilistic atlas of the deep cerebellar 
nuclei.29 This enabled us to overcome some of the 
limitations of previous studies by obtaining reliable 
quantitative signal intensity measurements even if the 
DN was not readily visible on T1w or T2w images.
Hyperintensity of the DN on unenhanced T1w images 
in MS patients has been described previously by 
Roccatagliata et al.19 who reported this feature in 
19.3% of MS patients. They found a positive associa-
tion with disease severity (EDSS score > 3.5), disease 
subtype (46% in secondary-progressive multiple scle-
rosis (SPMS) vs 8% in RRMS) and radiological 
markers of disease duration and activity (high lesion 
load on T2w MRI and brain atrophy). We also 
observed a significant correlation between DPSIR at 
baseline and disease duration, severity and subtype 
that might partially explain the different DPSIRs at 
baseline between the two GBCA groups. It has been 
suggested that DN hyperintensity in MS patients is 
caused by disease-associated neurodegeneration of 
cerebral and cerebellar grey matter, as well as iron 
deposition.21,34,35 However, an association with the 
number of previous GBCA administrations was not 
examined. A case report by Absinta et al.20 who 
reported an MS patient with marked bilateral DN T1 
hyperintensity who showed only mild disease symp-
toms but had probably received a large number of 
contrast-enhanced MRI examinations before points to 
a different explanation. In light of the results from our 
study, an alternative explanation could be that patients 
with highly active and/or long-standing disease were 
likely to have received a higher number of contrast-
enhanced MRI scans which in turn caused the signal 
intensity elevations. Our results cannot, however, 
exclude the possibility that progressive neurodegen-
eration or iron deposition also contribute to the 
observed effect. Theoretically, there might also be 
interactions between the suggested mechanisms by 
means of Gd-induced accelerated neurodegeneration, 
or Gd-induced disruption of the blood–brain barrier 
leading to iron accumulation.
A limitation of our study is that the distribution of the 
field strengths (1.5 T vs 3 T) was significantly differ-
ent between the two groups with 100% of patients 
who received Gd-DTPA and 71% of patients who 
received Gd-BT-DO3A being scanned at 1.5 T. While 
for spin-echo sequences the contrast-to-noise ratio is 
higher at 3 T as compared to 1.5 T which would have 
led to a higher sensitivity in detecting signal differ-
ences in the Gd-BT-DO3A group in our study, this is 
not necessarily the case for MPRAGE sequences due 
to the employed inversion recovery pulse. Unenhanced 
grey-to-white matter contrast would even be expected 
to decrease with higher field strengths which could 
have favoured missing signal changes in the Gd-BT-
DO3A group. The mean dosage used for Gd-BT-
DO3A was smaller compared to Gd-DTPA which 
could also have contributed to the lack of detection of 
signal changes in the Gd-BT-DO3A group. We there-
fore have performed only GBCA-specific analyses 
and do not report any between-group comparisons. 
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Additionally, MS subtype, EDSS score and time 
between scans differed between the two GBCA 
groups, but there was no evidence in post hoc analy-
ses that these imbalances influenced the results of our 
study. For the investigation of our hypothesis, we 
have limited our analysis to only one anatomic region 
(DN) because the DN has been shown to be the most 
affected region.
In conclusion, in our cohort, the administration of 
the linear Gd-DTPA is associated with T1 signal 
hyperintensity of the DN of MS patients on unen-
hanced MRI, most likely reflecting Gd deposition. 
This effect was not observed for the macrocyclic 
Gd-BT-DO3A. However, despite this more favourable 
result for Gd-BT-DO3A, our study cannot exclude 
the possibility that Gd-BT-DO3A accumulates in the 
DN or other brain regions. Since long-term clinical 
effects of cerebral Gd deposition are still unknown, 
the indication for GBCA administration should be 
strict. Given the current data, neurologists should 
order contrast-enhanced MRI only after careful con-
sideration of benefits and risks, and radiologists 
should give preference to macrocyclic agents, as 
these agents seem to be less prone to accumulate in 
cerebral grey matter and seem to have a better safety 
profile.
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